Pfizer and Blackstone Agree to Fund Berobenatide Development

Pfizer announced November 11 that Blackstone-managed funds will cover up to $1.5 billion of berobenatide development costs through 2028 in exchange for conditional milestone payments. Pfizer retains ownership and operating control.




